<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660839</url>
  </required_header>
  <id_info>
    <org_study_id>ACT14655</org_study_id>
    <secondary_id>U1111-1191-5573</secondary_id>
    <nct_id>NCT03660839</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria</brief_title>
  <official_title>A Randomized, Open Label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 Dose Levels of Artefenomel (OZ439) Given in Combination With Ferroquine (FQ) and FQ Alone, in African Patients With Uncomplicated Plasmodium Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To show the contribution of artefenomel (OZ439) to the clinical and parasiticidal effect of&#xD;
      OZ439/Ferroquine (FQ) combination by analyzing exposure-response of OZ439 measured by Day 28&#xD;
      polymerase chain reaction (PCR)-corrected adequate clinical and parasitological response&#xD;
      (ACPR) for the effect and the area under the curve (AUC) of OZ439 as pharmacokinetic (PK)&#xD;
      predictor.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate the exposure-response of OZ439 combined with FQ on crude Day 28 ACPR.&#xD;
&#xD;
        -  To evaluate the dose response of OZ439 combined with FQ on PCR-corrected and crude Day&#xD;
           28 ACPR.&#xD;
&#xD;
        -  To evaluate the dose-response of OZ439 combined with FQ on selected secondary endpoints.&#xD;
&#xD;
        -  To evaluate the safety and tolerability of different dosages of OZ439 in combination&#xD;
           with FQ and FQ alone.&#xD;
&#xD;
        -  To characterize the PK of OZ439 in plasma, and of FQ and its active metabolite SSR97213&#xD;
           in blood.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study was up to 32 days, including up to 1 day screening period before&#xD;
      the single-dose treatment, 5 days of post-treatment surveillance (included 2 to 4 days&#xD;
      hospitalization) and 24±2 days follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2018</start_date>
  <completion_date type="Actual">November 6, 2019</completion_date>
  <primary_completion_date type="Actual">November 6, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 28 (ACPR28)</measure>
    <time_frame>Day 28</time_frame>
    <description>ACPR:absence of parasitemia at Day 28, irrespective of axillary temperature(AT), participants not meeting any criteria of early therapy failure(ETF):Danger signs(DS)/symptoms of complicated(SoC)/severe malaria(SM) at Day 1, 2 or 3 in presence of parasitemia, concomitant to at least 1 positive parasitemia;or parasitemia on Day 2 &gt;Day 0 irrespective of AT;or parasitemia on Day 3 with AT&gt;=37.5 degree Celsius (°C);or parasitemia count on Day 3 &gt;=25 percent (%) on Day 0, or late clinical failure (LCF):DS/SM in presence of parasitemia between Day 4 and 28,concomitant to at least one positive parasitemia;or presence of parasitemia and AT&gt;=37.5°C on Day 4 to Day 28, or late parasitological failure(LPF):presence of parasitemia between Day 7 and 28 and AT&lt;37.5°C and without rescue therapy. PCR-corrected ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with genotype identical to that present at Baseline), excluding participants with reinfection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Crude Adequate Clinical and Parasitological Response at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>ACPR: absence of parasitemia at Day 28, irrespective of AT, in participants not meeting any criteria of ETF: DS/SoC/SM at Day 1, 2 or 3 in presence of parasitemia, concomitant to at least 1 positive parasitemia; or parasitemia on Day 2 &gt; Day 0 irrespective of AT; or parasitemia on Day 3 with AT &gt;=37.5°C; or parasitemia count on Day 3 &gt;=25% on Day 0, or LCF: DS/SM in presence of parasitemia between Day 4 and 28, concomitant to at least one positive parasitemia; or presence of parasitemia and AT&gt;=37.5°C on Day 4 to Day 28, or LPF: presence of parasitemia between Day 7 and 28 and AT&lt;37.5°C or having rescue therapy for malaria. PCR-corrected ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with genotype identical to that present at Baseline), excluding participants with re-infection, whereas crude ACPR does not distinguish reinfection (new clone of parasite) or recrudescence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasitemia: Change From Baseline in Number of Parasites Per Microliter of Blood at 6, 12, 18, 24, 30, 36, 48, 72, 96, 120, 144 and 168 Hours</measure>
    <time_frame>Baseline, 6, 12, 18, 24, 30, 36, 48, 72, 96, 120, 144 and 168 hours post-dose</time_frame>
    <description>Parasitemia (quantitative content of parasites present in the blood) at baseline until Day 7 (i.e. 168 hours) was assessed by optical microscope.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Parasite Reduction Ratio (PRR) at 24 Hours, 48 Hours, and 72 Hours</measure>
    <time_frame>Baseline, 24, 48 and 72 hours post-dose</time_frame>
    <description>The observed PRR was defined as the ratio of the number of parasites at time t=0 (baseline) divided by the parasite count at each specified time t (post-treatment). If the post dose parasite count = 0 (due to a negative parasitemia) then a value of 1 parasite per microliter was imputed to allow a parasite reduction ratio calculation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 50% and 99% Parasite Reduction</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time to 50% and 99% parasite reduction was defined as time needed for the parasitemia (quantitative content of parasites present in blood) to be reduced to 50% and 99% of the initial value, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Clearance Time (PCT)</measure>
    <time_frame>From the start of study drug administration up to the time of the first negative blood film (up to Day 28)</time_frame>
    <description>PCT was defined as the time (in hours) from the start of study drug administration until the time of first negative blood film (no asexual parasites by microscopy). This first negative film was confirmed by a second negative film which was taken &gt;=6 to &lt;=12 hours of the first film. If the second film was performed &lt;6 hours or &gt;12 hours of the first film, then the parasite clearance was confirmed or invalidated by the third (thick) film following the second one, whatever the timing of this third film: If the third film was negative, then the clearance was considered confirmed and if the third film was positive, then the clearance was invalidated. Kaplan-Meier method was used for the estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Clearance Rate</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Parasite clearance rate (k) is the minus slope of the natural logarithm parasitemia versus time linear relationship, after exclusion of outliers, lag phase and Tail, using the worldwide antimalarial resistance network, Parasite Clearance Estimator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Re-emergence</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time to re-emergence (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection irrespective of genotype. Re-emergence was confirmed by microscopy (positive blood smear). Participants with confirmed parasite clearance were included in the analysis and Kaplan-Meier method was used for estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recrudescence</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time to recrudescence (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline. Recrudescence was confirmed by PCR analysis. Participants with confirmed parasite clearance were included in the analysis and Kaplan-Meier method was used for estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Re-infection</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time to re-infection (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection with a genotype that differed from that of parasites present at Baseline. Re-infection was confirmed by PCR analysis. Participants with confirmed parasite clearance were involved in the analysis and Kaplan-Maier method was used for estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Elapsed Below the Limit of Quantification (LOQ) of Parasitemia</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>The time elapsed below LOQ (LOQ expressed in parasites/microliter) of parasitemia (quantitative content of parasites present in the blood) was defined as the time (in days) for which no parasites were seen i.e., time corresponding to PCT, up to the time of occurrence of a new malaria infection or recrudescence. If there was no occurrence of a new malaria infection or recrudescence, then this was the time corresponding to the first negative thick blood film, until the end of study. PCT (k) is the minus slope of the natural logarithm parasitemia versus time linear relationship, after exclusion of outliers, lag phase and Tail, using the worldwide antimalarial resistance network, Parasite clearance estimator. Participants with confirmed parasite clearance were involved in the analysis and Kaplan-Meier method was used for estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESI)</measure>
    <time_frame>From Baseline up to Day 28</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. SAEs were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment phase that was defined as the time from the start of study drug up to the Day 28. AE of special interest (AESI) was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Concentration of OZ439 in Plasma</measure>
    <time_frame>1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose</time_frame>
    <description>Concentrations of OZ439 in plasma was analyzed by liquid chromatography tandem mass spectroscopy (LC-MS/MS). The lower limit of quantification (LLOQ) was 1 nanograms per milliliter for analysis of OZ439. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Concentration of FQ and Its Active Metabolite SSR97213 in Blood</measure>
    <time_frame>1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose</time_frame>
    <description>Concentrations of FQ and SSR97213 in blood was analyzed by LC-MS/MS. The LLOQ was 5 nanograms per milliliter for analysis of FQ and SSR97213.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Artefenomel</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose</time_frame>
    <description>Cmax is the maximum observed plasma concentration of Artefenomel. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time to Reach Maximum Plasma Concentration (Tmax) of Artefenomel</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose</time_frame>
    <description>tmax is the time taken by the drug to reach the maximum plasma concentration. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Plasma Concentration at 168 Hours Post-dose (C168h) of Artefenomel</measure>
    <time_frame>At 168 hours post-dose</time_frame>
    <description>The observed plasma concentration of artefenomel post 168 hours of drug administration. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) Form Time 0 to Infinity (AUC0-inf]) of Artefenomel</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to infinity. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Terminal Half-life (t1/2) of Artefenomel</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose</time_frame>
    <description>Terminal t1/2 is defined as the time required for the plasma concentration of a drug to decrease by half of its initial concentration. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Observed Plasma Concentration of Ferroquine and Its Active Metabolite SSR97213</measure>
    <time_frame>Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose</time_frame>
    <description>Cmax is the maximum observed plasma concentration of Ferroquine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time to Reach Maximum Plasma Concentration of Ferroquine and Its Active Metabolite SSR97213</measure>
    <time_frame>Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose</time_frame>
    <description>tmax is the time taken by the drug to reach the maximum plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Plasma Concentration at 168 Hours Post-dose of Ferroquine and Its Active Metabolite SSR97213</measure>
    <time_frame>At 168 hours post-dose</time_frame>
    <description>The observed plasma concentration of FQ and SSR97213 post 168 hours of FQ administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve Form Time 0 to Day 28 (AUC0-28) of Ferroquine and Its Active Metabolite SSR97213</measure>
    <time_frame>Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to Day 28 (i.e. 672 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve From Time 0 to Infinity of Ferroquine and Its Active Metabolite SSR97213</measure>
    <time_frame>Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Terminal Half-life of Ferroquine</measure>
    <time_frame>Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose</time_frame>
    <description>Terminal t1/2 is defined as the time required for the plasma concentration of a drug to decrease by half of its initial concentration.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Plasmodium Falciparum Infection</condition>
  <arm_group>
    <arm_group_label>Ferroquine 400 milligram (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferroquine 400 mg + Artefenomel 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferroquine 400 mg + Artefenomel 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferroquine 400 mg + Artefenomel 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artefenomel (OZ439)</intervention_name>
    <description>Pharmaceutical form: Granules for oral suspension Route of administration: Oral</description>
    <arm_group_label>Ferroquine 400 mg + Artefenomel 1000 mg</arm_group_label>
    <arm_group_label>Ferroquine 400 mg + Artefenomel 300 mg</arm_group_label>
    <arm_group_label>Ferroquine 400 mg + Artefenomel 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferroquine (SSR97193)</intervention_name>
    <description>Pharmaceutical form: Capsule Route of administration: Oral</description>
    <arm_group_label>Ferroquine 400 mg + Artefenomel 1000 mg</arm_group_label>
    <arm_group_label>Ferroquine 400 mg + Artefenomel 300 mg</arm_group_label>
    <arm_group_label>Ferroquine 400 mg + Artefenomel 600 mg</arm_group_label>
    <arm_group_label>Ferroquine 400 milligram (mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
        Participants (14-69 years old inclusive) with body weight within 35 and 90 kilograms (kg),&#xD;
        with uncomplicated Plasmodium falciparum (P. falciparum) malaria, with a fever as defined&#xD;
        with axillary temperature greater than or equal to (&gt;=) 37.5 degree Celsius (°C) or oral/&#xD;
        rectal/ tympanic temperature &gt;=38°C or history of fever in the previous 24 hours (history&#xD;
        of fever was documented), with a mono-infection with P. falciparum and parasitemia&#xD;
        (microscopically, blood smear) &gt;= 3,000 and less than or equal to (&lt;=) 50,000 asexual&#xD;
        parasites per microliter of blood.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Presence of severe malaria.&#xD;
&#xD;
          -  Known history or evidence of clinically significant gastrointestinal, cardiovascular,&#xD;
             hepatic, renal, hematological, respiratory, endocrine, immunological, infectious,&#xD;
             neurological (in particular convulsions), malignancy, psychiatric disease or symptoms&#xD;
             which, in the judgment of the investigator, might confuse the interpretation of the&#xD;
             safety information.&#xD;
&#xD;
          -  Severe vomiting defined as more than 3 times in the 24 hours prior to enrollment in&#xD;
             the study or inability to tolerate oral treatment or severe diarrhea defined as 3 or&#xD;
             more watery stools per day.&#xD;
&#xD;
          -  Severe malnutrition defined as a body mass index of less than 16 kg per meter square&#xD;
             for adults and for children Z-score less than (&lt;) -3 or weight for age (%) of the&#xD;
             median &lt;60.&#xD;
&#xD;
          -  Splenectomized participants or presence of surgical scar on left hypochondrium.&#xD;
&#xD;
          -  Known history of hypersensitivity, allergic, or anaphylactoid reactions to FQ or other&#xD;
             amino quinolines or to OZ439 or OZ277 or any of the excipients.&#xD;
&#xD;
          -  Participant treated with anti-malarial treatment:&#xD;
&#xD;
          -  With piperaquine phosphate-based compound, mefloquine, naphthoquine or&#xD;
             sulphadoxine/pyrimethamine within the previous 6 weeks.&#xD;
&#xD;
          -  With amodiaquine or chloroquine within the previous 4 weeks.&#xD;
&#xD;
          -  With quinine, halofantrine, lumefantrine-based compounds and any other anti-malarial&#xD;
             treatment or antibiotics with antimalarial activity (including cotrimoxazole,&#xD;
             tetracyclines, quinolones and fluoroquinolones, and azithromycin) within the past 14&#xD;
             days.&#xD;
&#xD;
          -  With any herbal products or traditional medicines, within the past 7 days.&#xD;
&#xD;
          -  Previous treatment within 5 times the half-life or within the last 14 days, whichever&#xD;
             the longest, which were: strong Cytochrome P450 (CYP) 2C or CYP3A inhibitors and/or&#xD;
             moderate inhibitors but inhibiting both CYP2C and CYP3A and/or CYP inducers.&#xD;
&#xD;
          -  Any treatment known to induce a prolongation of QT interval.&#xD;
&#xD;
          -  Participated in any trial investigating OZ439 and/or FQ compounds.&#xD;
&#xD;
          -  Previous participation in any malaria vaccine study or received malaria vaccine in any&#xD;
             other circumstance.&#xD;
&#xD;
          -  Enrolled in another clinical trial within the past 4 weeks or during the study period.&#xD;
&#xD;
          -  Mixed Plasmodium infection.&#xD;
&#xD;
          -  Presence of Hepatitis A - immunoglobulin, Hepatitis B surface antigen or Hepatitis C&#xD;
             virus antibody and/or known to had active Hepatitis C virus ribonucleic acid.&#xD;
&#xD;
          -  Laboratory parameters with abnormalities deemed clinically significant by the&#xD;
             investigator.&#xD;
&#xD;
          -  Abnormal Liver Function Test: aspartate transferase greater than (&gt;) 2 upper limit of&#xD;
             normal range (ULN), or alanine transferase &gt;2 ULN or total bilirubin &gt;1.5 ULN.&#xD;
&#xD;
          -  Positive pregnancy test at study screening for female participants of childbearing&#xD;
             potential.&#xD;
&#xD;
          -  QT interval corrected using Fridericia formula (QTcF) &gt;450 milliseconds at screening&#xD;
             or pre-dose.&#xD;
&#xD;
          -  Hypokalemia (&lt;3.5 millimoles per liter [mmol/L]), hypocalcemia (&lt;2.0 mmol/L) or&#xD;
             hypomagnesemia (&lt;0.5 mmol/L) at screening or pre-dose.&#xD;
&#xD;
          -  Family history of sudden death or of congenital prolongation of the QT interval or&#xD;
             known congenital prolongation of the QT-interval or any clinical condition known to&#xD;
             prolong the QT interval e.g., participants with a history of symptomatic cardiac&#xD;
             arrhythmias including atrial fibrillation or with clinically relevant bradycardia.&#xD;
&#xD;
          -  Participant not suitable for participation, whatever the reason, as judged by the&#xD;
             Investigator, included medical or clinical conditions, or participants potentially at&#xD;
             risk of noncompliance to study procedures or unable to drink.&#xD;
&#xD;
        The above information was not intended to contain all considerations relevant to a&#xD;
        participant's potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 2040001</name>
      <address>
        <city>Cotonou</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8540002</name>
      <address>
        <city>Banfora</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8540001</name>
      <address>
        <city>Ouagadougou</city>
        <zip>01 BP218</zip>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2660002</name>
      <address>
        <city>Lambarene</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2660001</name>
      <address>
        <city>Libreville</city>
        <zip>B.P. 4009</zip>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4040002</name>
      <address>
        <city>Siaya</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8000001</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Benin</country>
    <country>Burkina Faso</country>
    <country>Gabon</country>
    <country>Kenya</country>
    <country>Uganda</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <results_first_submitted>November 5, 2020</results_first_submitted>
  <results_first_submitted_qc>November 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2020</results_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artefenomel</mesh_term>
    <mesh_term>Ferroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03660839/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03660839/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted at 7 active sites in 5 countries. Total of 448 participants were screened between 11 September 2018 and 09 October 2019, of which 140 were randomized to 1 of 4 treatment arms and those who failed to meet inclusion criteria were considered as screen failure.</recruitment_details>
      <pre_assignment_details>All eligible participants were randomized via a centralized randomization system using interactive response technology to 1 of the 4 arms in 1:1:1:1 ratio. Day 0 (drug administration day, per protocol) was considered as Day 1 for all analysis using Safety population as per Clinical Data Interchange Standards Consortium convention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ferroquine (FQ) 400 Milligram (mg)</title>
          <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
        </group>
        <group group_id="P2">
          <title>Ferroquine 400 mg + Artefenomel (OZ439) 300 mg</title>
          <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
        </group>
        <group group_id="P3">
          <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
          <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
        </group>
        <group group_id="P4">
          <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
          <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Ferroquine 400 mg</title>
          <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
        </group>
        <group group_id="B2">
          <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
          <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
        </group>
        <group group_id="B3">
          <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
          <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
        </group>
        <group group_id="B4">
          <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
          <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="33"/>
            <count group_id="B5" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.4" spread="13.20"/>
                    <measurement group_id="B2" value="21.8" spread="11.49"/>
                    <measurement group_id="B3" value="20.7" spread="8.57"/>
                    <measurement group_id="B4" value="22.2" spread="11.28"/>
                    <measurement group_id="B5" value="22.5" spread="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 28 (ACPR28)</title>
        <description>ACPR:absence of parasitemia at Day 28, irrespective of axillary temperature(AT), participants not meeting any criteria of early therapy failure(ETF):Danger signs(DS)/symptoms of complicated(SoC)/severe malaria(SM) at Day 1, 2 or 3 in presence of parasitemia, concomitant to at least 1 positive parasitemia;or parasitemia on Day 2 &gt;Day 0 irrespective of AT;or parasitemia on Day 3 with AT&gt;=37.5 degree Celsius (°C);or parasitemia count on Day 3 &gt;=25 percent (%) on Day 0, or late clinical failure (LCF):DS/SM in presence of parasitemia between Day 4 and 28,concomitant to at least one positive parasitemia;or presence of parasitemia and AT&gt;=37.5°C on Day 4 to Day 28, or late parasitological failure(LPF):presence of parasitemia between Day 7 and 28 and AT&lt;37.5°C and without rescue therapy. PCR-corrected ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with genotype identical to that present at Baseline), excluding participants with reinfection.</description>
        <time_frame>Day 28</time_frame>
        <population>Pharmacokinetic/Pharmacodynamic (PK/PD) efficacy population: who received at least 1 dose of OZ439/FQ with parasitologically confirmed Plasmodium falciparum at baseline with data post-randomization, 1 evaluable PK blood sample (OZ439/FQ) post dose, adequate documentation of dosing &amp; sampling date, without any major protocol deviation related to drug administration (e.g. vomiting after drug intake). Here,&quot;overall number of participants analyzed&quot;=participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 28 (ACPR28)</title>
          <description>ACPR:absence of parasitemia at Day 28, irrespective of axillary temperature(AT), participants not meeting any criteria of early therapy failure(ETF):Danger signs(DS)/symptoms of complicated(SoC)/severe malaria(SM) at Day 1, 2 or 3 in presence of parasitemia, concomitant to at least 1 positive parasitemia;or parasitemia on Day 2 &gt;Day 0 irrespective of AT;or parasitemia on Day 3 with AT&gt;=37.5 degree Celsius (°C);or parasitemia count on Day 3 &gt;=25 percent (%) on Day 0, or late clinical failure (LCF):DS/SM in presence of parasitemia between Day 4 and 28,concomitant to at least one positive parasitemia;or presence of parasitemia and AT&gt;=37.5°C on Day 4 to Day 28, or late parasitological failure(LPF):presence of parasitemia between Day 7 and 28 and AT&lt;37.5°C and without rescue therapy. PCR-corrected ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with genotype identical to that present at Baseline), excluding participants with reinfection.</description>
          <population>Pharmacokinetic/Pharmacodynamic (PK/PD) efficacy population: who received at least 1 dose of OZ439/FQ with parasitologically confirmed Plasmodium falciparum at baseline with data post-randomization, 1 evaluable PK blood sample (OZ439/FQ) post dose, adequate documentation of dosing &amp; sampling date, without any major protocol deviation related to drug administration (e.g. vomiting after drug intake). Here,&quot;overall number of participants analyzed&quot;=participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" lower_limit="62.1" upper_limit="91.5"/>
                    <measurement group_id="O2" value="90.3" lower_limit="75.1" upper_limit="96.7"/>
                    <measurement group_id="O3" value="90.9" lower_limit="76.4" upper_limit="96.9"/>
                    <measurement group_id="O4" value="87.1" lower_limit="71.1" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Crude Adequate Clinical and Parasitological Response at Day 28</title>
        <description>ACPR: absence of parasitemia at Day 28, irrespective of AT, in participants not meeting any criteria of ETF: DS/SoC/SM at Day 1, 2 or 3 in presence of parasitemia, concomitant to at least 1 positive parasitemia; or parasitemia on Day 2 &gt; Day 0 irrespective of AT; or parasitemia on Day 3 with AT &gt;=37.5°C; or parasitemia count on Day 3 &gt;=25% on Day 0, or LCF: DS/SM in presence of parasitemia between Day 4 and 28, concomitant to at least one positive parasitemia; or presence of parasitemia and AT&gt;=37.5°C on Day 4 to Day 28, or LPF: presence of parasitemia between Day 7 and 28 and AT&lt;37.5°C or having rescue therapy for malaria. PCR-corrected ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with genotype identical to that present at Baseline), excluding participants with re-infection, whereas crude ACPR does not distinguish reinfection (new clone of parasite) or recrudescence.</description>
        <time_frame>Day 28</time_frame>
        <population>Analysis was performed on PK/PD efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Crude Adequate Clinical and Parasitological Response at Day 28</title>
          <description>ACPR: absence of parasitemia at Day 28, irrespective of AT, in participants not meeting any criteria of ETF: DS/SoC/SM at Day 1, 2 or 3 in presence of parasitemia, concomitant to at least 1 positive parasitemia; or parasitemia on Day 2 &gt; Day 0 irrespective of AT; or parasitemia on Day 3 with AT &gt;=37.5°C; or parasitemia count on Day 3 &gt;=25% on Day 0, or LCF: DS/SM in presence of parasitemia between Day 4 and 28, concomitant to at least one positive parasitemia; or presence of parasitemia and AT&gt;=37.5°C on Day 4 to Day 28, or LPF: presence of parasitemia between Day 7 and 28 and AT&lt;37.5°C or having rescue therapy for malaria. PCR-corrected ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with genotype identical to that present at Baseline), excluding participants with re-infection, whereas crude ACPR does not distinguish reinfection (new clone of parasite) or recrudescence.</description>
          <population>Analysis was performed on PK/PD efficacy population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.5" lower_limit="46.9" upper_limit="78.9"/>
                    <measurement group_id="O2" value="81.8" lower_limit="65.6" upper_limit="91.4"/>
                    <measurement group_id="O3" value="77.8" lower_limit="61.9" upper_limit="88.3"/>
                    <measurement group_id="O4" value="78.1" lower_limit="61.2" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasitemia: Change From Baseline in Number of Parasites Per Microliter of Blood at 6, 12, 18, 24, 30, 36, 48, 72, 96, 120, 144 and 168 Hours</title>
        <description>Parasitemia (quantitative content of parasites present in the blood) at baseline until Day 7 (i.e. 168 hours) was assessed by optical microscope.</description>
        <time_frame>Baseline, 6, 12, 18, 24, 30, 36, 48, 72, 96, 120, 144 and 168 hours post-dose</time_frame>
        <population>Analysis was performed on modified intention-to-treat (mITT) population which included all randomized participants with parasitological confirmed P.falciparum malaria at baseline with parasitemia data post-randomization, received the single administration of OZ439/FQ. Here, &quot;number analyzed&quot; = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Parasitemia: Change From Baseline in Number of Parasites Per Microliter of Blood at 6, 12, 18, 24, 30, 36, 48, 72, 96, 120, 144 and 168 Hours</title>
          <description>Parasitemia (quantitative content of parasites present in the blood) at baseline until Day 7 (i.e. 168 hours) was assessed by optical microscope.</description>
          <population>Analysis was performed on modified intention-to-treat (mITT) population which included all randomized participants with parasitological confirmed P.falciparum malaria at baseline with parasitemia data post-randomization, received the single administration of OZ439/FQ. Here, &quot;number analyzed&quot; = participants with available data for each specified category.</population>
          <units>parasites per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17496.0" spread="11889.55"/>
                    <measurement group_id="O2" value="18799.6" spread="13559.14"/>
                    <measurement group_id="O3" value="15171.9" spread="13012.53"/>
                    <measurement group_id="O4" value="20546.8" spread="13835.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 6 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1349.3" spread="11331.78"/>
                    <measurement group_id="O2" value="-96.9" spread="11699.28"/>
                    <measurement group_id="O3" value="8515.4" spread="44264.14"/>
                    <measurement group_id="O4" value="893.2" spread="21052.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 12 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5721.5" spread="12441.39"/>
                    <measurement group_id="O2" value="-11471.6" spread="13399.27"/>
                    <measurement group_id="O3" value="-4156.6" spread="34663.71"/>
                    <measurement group_id="O4" value="-11319.4" spread="15490.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 18 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9181.2" spread="11892.89"/>
                    <measurement group_id="O2" value="-17021.4" spread="13015.29"/>
                    <measurement group_id="O3" value="-9447.5" spread="32303.36"/>
                    <measurement group_id="O4" value="-18281.9" spread="13796.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 24 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14238.4" spread="11402.25"/>
                    <measurement group_id="O2" value="-17939.0" spread="13061.86"/>
                    <measurement group_id="O3" value="-10674.6" spread="29868.45"/>
                    <measurement group_id="O4" value="-19461.9" spread="14049.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 30 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16571.1" spread="12354.88"/>
                    <measurement group_id="O2" value="-19110.5" spread="13556.35"/>
                    <measurement group_id="O3" value="-13299.6" spread="17452.15"/>
                    <measurement group_id="O4" value="-19657.5" spread="14393.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 36 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17036.9" spread="12307.57"/>
                    <measurement group_id="O2" value="-18792.2" spread="13548.16"/>
                    <measurement group_id="O3" value="-14573.9" spread="13623.86"/>
                    <measurement group_id="O4" value="-19587.9" spread="14051.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 48 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17595.3" spread="12037.99"/>
                    <measurement group_id="O2" value="-17706.1" spread="13389.25"/>
                    <measurement group_id="O3" value="-14542.3" spread="13547.11"/>
                    <measurement group_id="O4" value="-20327.7" spread="13739.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 72 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18231.8" spread="11801.65"/>
                    <measurement group_id="O2" value="-18396.3" spread="13091.47"/>
                    <measurement group_id="O3" value="-15333.7" spread="13382.41"/>
                    <measurement group_id="O4" value="-20314.2" spread="13980.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 96 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18287.6" spread="12011.77"/>
                    <measurement group_id="O2" value="-19024.7" spread="13200.22"/>
                    <measurement group_id="O3" value="-15258.5" spread="13191.95"/>
                    <measurement group_id="O4" value="-20662.0" spread="14108.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 120 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19280.0" spread="12145.86"/>
                    <measurement group_id="O2" value="-19024.7" spread="13200.22"/>
                    <measurement group_id="O3" value="-15265.3" spread="13190.14"/>
                    <measurement group_id="O4" value="-20350.4" spread="14010.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 144 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18526.0" spread="11889.52"/>
                    <measurement group_id="O2" value="-19023.3" spread="13198.28"/>
                    <measurement group_id="O3" value="-15254.5" spread="13190.39"/>
                    <measurement group_id="O4" value="-20029.7" spread="14121.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at 168 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18962.8" spread="11813.20"/>
                    <measurement group_id="O2" value="-18922.2" spread="13141.19"/>
                    <measurement group_id="O3" value="-15268.5" spread="13388.49"/>
                    <measurement group_id="O4" value="-20349.5" spread="14010.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Parasite Reduction Ratio (PRR) at 24 Hours, 48 Hours, and 72 Hours</title>
        <description>The observed PRR was defined as the ratio of the number of parasites at time t=0 (baseline) divided by the parasite count at each specified time t (post-treatment). If the post dose parasite count = 0 (due to a negative parasitemia) then a value of 1 parasite per microliter was imputed to allow a parasite reduction ratio calculation.</description>
        <time_frame>Baseline, 24, 48 and 72 hours post-dose</time_frame>
        <population>Analysis was performed on mITT population. Here, 'number analyzed' = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Parasite Reduction Ratio (PRR) at 24 Hours, 48 Hours, and 72 Hours</title>
          <description>The observed PRR was defined as the ratio of the number of parasites at time t=0 (baseline) divided by the parasite count at each specified time t (post-treatment). If the post dose parasite count = 0 (due to a negative parasitemia) then a value of 1 parasite per microliter was imputed to allow a parasite reduction ratio calculation.</description>
          <population>Analysis was performed on mITT population. Here, 'number analyzed' = participants with available data for each specified category.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Hour 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="638.436" spread="2013.8609"/>
                    <measurement group_id="O2" value="5921.197" spread="11566.1520"/>
                    <measurement group_id="O3" value="5715.046" spread="9364.8892"/>
                    <measurement group_id="O4" value="7929.720" spread="12675.8348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Hour 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9709.093" spread="13987.7127"/>
                    <measurement group_id="O2" value="17594.700" spread="13521.9507"/>
                    <measurement group_id="O3" value="13120.409" spread="13182.3022"/>
                    <measurement group_id="O4" value="19328.057" spread="14392.7604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Hour 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15655.447" spread="12806.4644"/>
                    <measurement group_id="O2" value="18069.583" spread="13409.1341"/>
                    <measurement group_id="O3" value="14561.409" spread="13657.0665"/>
                    <measurement group_id="O4" value="19125.715" spread="14516.8397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to 50% and 99% Parasite Reduction</title>
        <description>Time to 50% and 99% parasite reduction was defined as time needed for the parasitemia (quantitative content of parasites present in blood) to be reduced to 50% and 99% of the initial value, respectively.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>Analysis was performed on mITT population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to 50% and 99% Parasite Reduction</title>
          <description>Time to 50% and 99% parasite reduction was defined as time needed for the parasitemia (quantitative content of parasites present in blood) to be reduced to 50% and 99% of the initial value, respectively.</description>
          <population>Analysis was performed on mITT population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time to 50% Parasite reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.07" spread="5.604"/>
                    <measurement group_id="O2" value="7.74" spread="4.636"/>
                    <measurement group_id="O3" value="7.78" spread="3.786"/>
                    <measurement group_id="O4" value="9.47" spread="7.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to 99% Parasite reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.92" spread="9.988"/>
                    <measurement group_id="O2" value="19.33" spread="6.107"/>
                    <measurement group_id="O3" value="18.34" spread="5.523"/>
                    <measurement group_id="O4" value="22.95" spread="17.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasite Clearance Time (PCT)</title>
        <description>PCT was defined as the time (in hours) from the start of study drug administration until the time of first negative blood film (no asexual parasites by microscopy). This first negative film was confirmed by a second negative film which was taken &gt;=6 to &lt;=12 hours of the first film. If the second film was performed &lt;6 hours or &gt;12 hours of the first film, then the parasite clearance was confirmed or invalidated by the third (thick) film following the second one, whatever the timing of this third film: If the third film was negative, then the clearance was considered confirmed and if the third film was positive, then the clearance was invalidated. Kaplan-Meier method was used for the estimation.</description>
        <time_frame>From the start of study drug administration up to the time of the first negative blood film (up to Day 28)</time_frame>
        <population>Analysis was performed on mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Parasite Clearance Time (PCT)</title>
          <description>PCT was defined as the time (in hours) from the start of study drug administration until the time of first negative blood film (no asexual parasites by microscopy). This first negative film was confirmed by a second negative film which was taken &gt;=6 to &lt;=12 hours of the first film. If the second film was performed &lt;6 hours or &gt;12 hours of the first film, then the parasite clearance was confirmed or invalidated by the third (thick) film following the second one, whatever the timing of this third film: If the third film was negative, then the clearance was considered confirmed and if the third film was positive, then the clearance was invalidated. Kaplan-Meier method was used for the estimation.</description>
          <population>Analysis was performed on mITT population.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" lower_limit="48.0" upper_limit="72.0"/>
                    <measurement group_id="O2" value="30.0" lower_limit="30.0" upper_limit="30.0"/>
                    <measurement group_id="O3" value="30.0" lower_limit="24.1" upper_limit="30.1"/>
                    <measurement group_id="O4" value="30.0" lower_limit="24.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasite Clearance Rate</title>
        <description>Parasite clearance rate (k) is the minus slope of the natural logarithm parasitemia versus time linear relationship, after exclusion of outliers, lag phase and Tail, using the worldwide antimalarial resistance network, Parasite Clearance Estimator.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>Analysis was performed on mITT population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Parasite Clearance Rate</title>
          <description>Parasite clearance rate (k) is the minus slope of the natural logarithm parasitemia versus time linear relationship, after exclusion of outliers, lag phase and Tail, using the worldwide antimalarial resistance network, Parasite Clearance Estimator.</description>
          <population>Analysis was performed on mITT population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure.</population>
          <units>1 per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1956" spread="0.07627"/>
                    <measurement group_id="O2" value="0.3609" spread="0.09963"/>
                    <measurement group_id="O3" value="0.3962" spread="0.11983"/>
                    <measurement group_id="O4" value="0.3581" spread="0.12484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Re-emergence</title>
        <description>Time to re-emergence (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection irrespective of genotype. Re-emergence was confirmed by microscopy (positive blood smear). Participants with confirmed parasite clearance were included in the analysis and Kaplan-Meier method was used for estimation.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>Analysis was performed on mITT population. Here, &quot;overall number of participants analyzed&quot; = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Re-emergence</title>
          <description>Time to re-emergence (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection irrespective of genotype. Re-emergence was confirmed by microscopy (positive blood smear). Participants with confirmed parasite clearance were included in the analysis and Kaplan-Meier method was used for estimation.</description>
          <population>Analysis was performed on mITT population. Here, &quot;overall number of participants analyzed&quot; = participants evaluable for this outcome measure.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="28.0" upper_limit="NA">Median and upper limit of confidence interval (CI) was not estimable due to very low number of participants with events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI was not estimable due to very low number of participants with the events .</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI was not estimable due to very low number of participants with the events .</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI was not estimable due to very low number of participants with the events .</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recrudescence</title>
        <description>Time to recrudescence (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline. Recrudescence was confirmed by PCR analysis. Participants with confirmed parasite clearance were included in the analysis and Kaplan-Meier method was used for estimation.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>Analysis was performed on mITT population. Here, &quot;overall number of participants analyzed&quot; = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recrudescence</title>
          <description>Time to recrudescence (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline. Recrudescence was confirmed by PCR analysis. Participants with confirmed parasite clearance were included in the analysis and Kaplan-Meier method was used for estimation.</description>
          <population>Analysis was performed on mITT population. Here, &quot;overall number of participants analyzed&quot; = participants evaluable for this outcome measure.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI was not estimable due to very low number of participants with the events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI was not estimable due to very low number of participants with the events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI was not estimable due to very low number of participants with the events.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI was not estimable due to very low number of participants with the events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Re-infection</title>
        <description>Time to re-infection (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection with a genotype that differed from that of parasites present at Baseline. Re-infection was confirmed by PCR analysis. Participants with confirmed parasite clearance were involved in the analysis and Kaplan-Maier method was used for estimation.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>Analysis was performed on mITT population. Here, &quot;overall number of participants analyzed&quot; = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Re-infection</title>
          <description>Time to re-infection (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection with a genotype that differed from that of parasites present at Baseline. Re-infection was confirmed by PCR analysis. Participants with confirmed parasite clearance were involved in the analysis and Kaplan-Maier method was used for estimation.</description>
          <population>Analysis was performed on mITT population. Here, &quot;overall number of participants analyzed&quot; = participants evaluable for this outcome measure.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI was not estimable due to very low number of participants with the events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI was not estimable due to very low number of participants with the events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI was not estimable due to very low number of participants with the events.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI was not estimable due to very low number of participants with the events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Elapsed Below the Limit of Quantification (LOQ) of Parasitemia</title>
        <description>The time elapsed below LOQ (LOQ expressed in parasites/microliter) of parasitemia (quantitative content of parasites present in the blood) was defined as the time (in days) for which no parasites were seen i.e., time corresponding to PCT, up to the time of occurrence of a new malaria infection or recrudescence. If there was no occurrence of a new malaria infection or recrudescence, then this was the time corresponding to the first negative thick blood film, until the end of study. PCT (k) is the minus slope of the natural logarithm parasitemia versus time linear relationship, after exclusion of outliers, lag phase and Tail, using the worldwide antimalarial resistance network, Parasite clearance estimator. Participants with confirmed parasite clearance were involved in the analysis and Kaplan-Meier method was used for estimation.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>Analysis was performed on mITT population. Here, &quot;overall number of participants analyzed&quot; = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Elapsed Below the Limit of Quantification (LOQ) of Parasitemia</title>
          <description>The time elapsed below LOQ (LOQ expressed in parasites/microliter) of parasitemia (quantitative content of parasites present in the blood) was defined as the time (in days) for which no parasites were seen i.e., time corresponding to PCT, up to the time of occurrence of a new malaria infection or recrudescence. If there was no occurrence of a new malaria infection or recrudescence, then this was the time corresponding to the first negative thick blood film, until the end of study. PCT (k) is the minus slope of the natural logarithm parasitemia versus time linear relationship, after exclusion of outliers, lag phase and Tail, using the worldwide antimalarial resistance network, Parasite clearance estimator. Participants with confirmed parasite clearance were involved in the analysis and Kaplan-Meier method was used for estimation.</description>
          <population>Analysis was performed on mITT population. Here, &quot;overall number of participants analyzed&quot; = participants evaluable for this outcome measure.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="23.0" upper_limit="26.0"/>
                    <measurement group_id="O2" value="26.0" lower_limit="26.0" upper_limit="27.0"/>
                    <measurement group_id="O3" value="26.5" lower_limit="26.0" upper_limit="27.0"/>
                    <measurement group_id="O4" value="26.0" lower_limit="26.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESI)</title>
        <description>An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. SAEs were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment phase that was defined as the time from the start of study drug up to the Day 28. AE of special interest (AESI) was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.</description>
        <time_frame>From Baseline up to Day 28</time_frame>
        <population>Analysis was performed on safety population: participants who received single administration of OZ439/FQ and were analyzed according to the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESI)</title>
          <description>An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. SAEs were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment phase that was defined as the time from the start of study drug up to the Day 28. AE of special interest (AESI) was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.</description>
          <population>Analysis was performed on safety population: participants who received single administration of OZ439/FQ and were analyzed according to the treatment actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any treatment-emergent SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any treatment-emergent AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE led to treatment discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE led to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Concentration of OZ439 in Plasma</title>
        <description>Concentrations of OZ439 in plasma was analyzed by liquid chromatography tandem mass spectroscopy (LC-MS/MS). The lower limit of quantification (LLOQ) was 1 nanograms per milliliter for analysis of OZ439. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
        <time_frame>1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose</time_frame>
        <population>Analysis was performed on PK population which included all participants who received OZ439 and had at least one evaluable blood sample for PK OZ439 post study drug administration and with adequate documentation of date of dosing and date of sampling. Here, 'number analyzed' = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Concentration of OZ439 in Plasma</title>
          <description>Concentrations of OZ439 in plasma was analyzed by liquid chromatography tandem mass spectroscopy (LC-MS/MS). The lower limit of quantification (LLOQ) was 1 nanograms per milliliter for analysis of OZ439. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
          <population>Analysis was performed on PK population which included all participants who received OZ439 and had at least one evaluable blood sample for PK OZ439 post study drug administration and with adequate documentation of date of dosing and date of sampling. Here, 'number analyzed' = participants with available data for each specified category.</population>
          <units>nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.641" spread="104.631"/>
                    <measurement group_id="O2" value="149.199" spread="87.153"/>
                    <measurement group_id="O3" value="188.423" spread="82.588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269.075" spread="59.803"/>
                    <measurement group_id="O2" value="450.218" spread="58.642"/>
                    <measurement group_id="O3" value="655.851" spread="58.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349.134" spread="54.880"/>
                    <measurement group_id="O2" value="576.673" spread="54.357"/>
                    <measurement group_id="O3" value="978.649" spread="60.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.375" spread="52.902"/>
                    <measurement group_id="O2" value="478.929" spread="87.523"/>
                    <measurement group_id="O3" value="865.581" spread="75.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.614" spread="60.229"/>
                    <measurement group_id="O2" value="164.028" spread="99.433"/>
                    <measurement group_id="O3" value="369.335" spread="85.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.526" spread="65.757"/>
                    <measurement group_id="O2" value="48.257" spread="107.605"/>
                    <measurement group_id="O3" value="84.167" spread="78.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.097" spread="54.492"/>
                    <measurement group_id="O2" value="14.611" spread="95.627"/>
                    <measurement group_id="O3" value="29.554" spread="83.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.224" spread="50.406"/>
                    <measurement group_id="O2" value="8.162" spread="77.493"/>
                    <measurement group_id="O3" value="16.665" spread="83.936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.144" spread="39.859"/>
                    <measurement group_id="O2" value="5.339" spread="61.816"/>
                    <measurement group_id="O3" value="8.596" spread="77.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.745" spread="38.466"/>
                    <measurement group_id="O2" value="3.408" spread="73.232"/>
                    <measurement group_id="O3" value="5.903" spread="78.608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>336 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.227" spread="19.402"/>
                    <measurement group_id="O2" value="1.970" spread="66.212"/>
                    <measurement group_id="O3" value="3.149" spread="58.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Concentration of FQ and Its Active Metabolite SSR97213 in Blood</title>
        <description>Concentrations of FQ and SSR97213 in blood was analyzed by LC-MS/MS. The LLOQ was 5 nanograms per milliliter for analysis of FQ and SSR97213.</description>
        <time_frame>1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose</time_frame>
        <population>Analysis was performed on PK population which included all participants who received FQ and had at least one evaluable blood sample for PK FQ post study drug administration and with adequate documentation of date of dosing and date of sampling. Here, 'number analyzed' = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Concentration of FQ and Its Active Metabolite SSR97213 in Blood</title>
          <description>Concentrations of FQ and SSR97213 in blood was analyzed by LC-MS/MS. The LLOQ was 5 nanograms per milliliter for analysis of FQ and SSR97213.</description>
          <population>Analysis was performed on PK population which included all participants who received FQ and had at least one evaluable blood sample for PK FQ post study drug administration and with adequate documentation of date of dosing and date of sampling. Here, 'number analyzed' = participants with available data for each specified category.</population>
          <units>nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour post-dose: FQ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.094" spread="80.476"/>
                    <measurement group_id="O2" value="27.214" spread="79.000"/>
                    <measurement group_id="O3" value="21.165" spread="55.491"/>
                    <measurement group_id="O4" value="26.599" spread="95.999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose: SSR97213</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.209" spread="54.030"/>
                    <measurement group_id="O2" value="10.375" spread="15.713"/>
                    <measurement group_id="O3" value="6.161" spread="9.504"/>
                    <measurement group_id="O4" value="6.805" spread="28.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose: FQ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.934" spread="87.235"/>
                    <measurement group_id="O2" value="100.569" spread="61.578"/>
                    <measurement group_id="O3" value="79.656" spread="74.707"/>
                    <measurement group_id="O4" value="97.007" spread="72.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose: SSR97213</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.079" spread="90.358"/>
                    <measurement group_id="O2" value="29.632" spread="49.701"/>
                    <measurement group_id="O3" value="18.377" spread="98.310"/>
                    <measurement group_id="O4" value="17.559" spread="68.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post-dose: FQ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.005" spread="75.045"/>
                    <measurement group_id="O2" value="92.657" spread="50.449"/>
                    <measurement group_id="O3" value="84.803" spread="75.544"/>
                    <measurement group_id="O4" value="95.062" spread="126.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post-dose: SSR97213</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.170" spread="82.875"/>
                    <measurement group_id="O2" value="28.098" spread="53.438"/>
                    <measurement group_id="O3" value="25.954" spread="88.481"/>
                    <measurement group_id="O4" value="20.687" spread="70.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose: FQ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.293" spread="70.724"/>
                    <measurement group_id="O2" value="82.639" spread="49.891"/>
                    <measurement group_id="O3" value="78.196" spread="72.454"/>
                    <measurement group_id="O4" value="82.990" spread="69.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose: SSR97213</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.131" spread="66.944"/>
                    <measurement group_id="O2" value="29.319" spread="48.679"/>
                    <measurement group_id="O3" value="25.304" spread="78.822"/>
                    <measurement group_id="O4" value="20.299" spread="63.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose: FQ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.621" spread="57.540"/>
                    <measurement group_id="O2" value="68.384" spread="50.887"/>
                    <measurement group_id="O3" value="59.106" spread="70.461"/>
                    <measurement group_id="O4" value="71.743" spread="61.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose: SSR97213</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.957" spread="61.856"/>
                    <measurement group_id="O2" value="24.385" spread="48.408"/>
                    <measurement group_id="O3" value="20.615" spread="77.739"/>
                    <measurement group_id="O4" value="18.203" spread="64.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose: FQ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.351" spread="52.316"/>
                    <measurement group_id="O2" value="53.211" spread="48.834"/>
                    <measurement group_id="O3" value="47.568" spread="61.373"/>
                    <measurement group_id="O4" value="51.250" spread="75.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose: SSR97213</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.874" spread="56.412"/>
                    <measurement group_id="O2" value="22.967" spread="55.037"/>
                    <measurement group_id="O3" value="19.826" spread="70.907"/>
                    <measurement group_id="O4" value="16.763" spread="69.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours post-dose: FQ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.343" spread="35.315"/>
                    <measurement group_id="O2" value="31.161" spread="47.829"/>
                    <measurement group_id="O3" value="31.373" spread="70.287"/>
                    <measurement group_id="O4" value="29.792" spread="76.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours post-dose: SSR97213</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.757" spread="46.038"/>
                    <measurement group_id="O2" value="20.059" spread="45.134"/>
                    <measurement group_id="O3" value="21.315" spread="68.366"/>
                    <measurement group_id="O4" value="17.756" spread="82.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hours post-dose: FQ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.973" spread="39.627"/>
                    <measurement group_id="O2" value="20.524" spread="39.625"/>
                    <measurement group_id="O3" value="21.543" spread="63.679"/>
                    <measurement group_id="O4" value="21.322" spread="62.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hours post-dose: SSR97213</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.308" spread="52.300"/>
                    <measurement group_id="O2" value="19.196" spread="46.115"/>
                    <measurement group_id="O3" value="20.463" spread="55.587"/>
                    <measurement group_id="O4" value="19.108" spread="62.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>336 hours post-dose: FQ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.543" spread="36.770"/>
                    <measurement group_id="O2" value="11.678" spread="38.490"/>
                    <measurement group_id="O3" value="12.469" spread="48.236"/>
                    <measurement group_id="O4" value="11.263" spread="82.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>336 hours post-dose: SSR97213</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.612" spread="45.485"/>
                    <measurement group_id="O2" value="14.797" spread="46.036"/>
                    <measurement group_id="O3" value="15.647" spread="47.974"/>
                    <measurement group_id="O4" value="13.686" spread="72.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>672 hours post-dose: FQ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.737" spread="18.832"/>
                    <measurement group_id="O2" value="7.623" spread="28.348"/>
                    <measurement group_id="O3" value="7.601" spread="29.047"/>
                    <measurement group_id="O4" value="7.342" spread="53.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>672 hours post-dose: SSR97213</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.751" spread="41.862"/>
                    <measurement group_id="O2" value="10.324" spread="33.482"/>
                    <measurement group_id="O3" value="10.977" spread="34.251"/>
                    <measurement group_id="O4" value="12.014" spread="59.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Artefenomel</title>
        <description>Cmax is the maximum observed plasma concentration of Artefenomel. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose</time_frame>
        <population>Analysis was performed on PK/PD efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Artefenomel</title>
          <description>Cmax is the maximum observed plasma concentration of Artefenomel. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
          <population>Analysis was performed on PK/PD efficacy population.</population>
          <units>nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277.3" spread="169"/>
                    <measurement group_id="O2" value="488.3" spread="232"/>
                    <measurement group_id="O3" value="920.6" spread="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Time to Reach Maximum Plasma Concentration (Tmax) of Artefenomel</title>
        <description>tmax is the time taken by the drug to reach the maximum plasma concentration. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose</time_frame>
        <population>Focus of PK assessment was to support the analysis of exposure versus efficacy relationship (PK and PD). Since tmax was not considered relevant to the objective of exposure-response analysis, data for this outcome measure were not collected and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Time to Reach Maximum Plasma Concentration (Tmax) of Artefenomel</title>
          <description>tmax is the time taken by the drug to reach the maximum plasma concentration. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
          <population>Focus of PK assessment was to support the analysis of exposure versus efficacy relationship (PK and PD). Since tmax was not considered relevant to the objective of exposure-response analysis, data for this outcome measure were not collected and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Plasma Concentration at 168 Hours Post-dose (C168h) of Artefenomel</title>
        <description>The observed plasma concentration of artefenomel post 168 hours of drug administration. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
        <time_frame>At 168 hours post-dose</time_frame>
        <population>Analysis was performed on PK/PD efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Plasma Concentration at 168 Hours Post-dose (C168h) of Artefenomel</title>
          <description>The observed plasma concentration of artefenomel post 168 hours of drug administration. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
          <population>Analysis was performed on PK/PD efficacy population.</population>
          <units>nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9251" spread="110"/>
                    <measurement group_id="O2" value="2.152" spread="202"/>
                    <measurement group_id="O3" value="4.445" spread="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration Curve (AUC) Form Time 0 to Infinity (AUC0-inf]) of Artefenomel</title>
        <description>Area under the plasma concentration versus time curve from time 0 to infinity. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose</time_frame>
        <population>Analysis was performed on PK/PD efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Curve (AUC) Form Time 0 to Infinity (AUC0-inf]) of Artefenomel</title>
          <description>Area under the plasma concentration versus time curve from time 0 to infinity. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
          <population>Analysis was performed on PK/PD efficacy population.</population>
          <units>micrograms*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.269" spread="113"/>
                    <measurement group_id="O2" value="6.46" spread="181"/>
                    <measurement group_id="O3" value="13.05" spread="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Terminal Half-life (t1/2) of Artefenomel</title>
        <description>Terminal t1/2 is defined as the time required for the plasma concentration of a drug to decrease by half of its initial concentration. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
        <time_frame>Pre-dose, 1, 2, 4, 6, 12, 24, 48, 72, 120, 168 and 336 hours post-dose</time_frame>
        <population>Focus of PK assessment was to support the analysis of exposure versus efficacy relationship (PK and PD). Since terminal t1/2 was not considered relevant to the objective of exposure-response analysis, therefore data for this outcome measure were not collected and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Terminal Half-life (t1/2) of Artefenomel</title>
          <description>Terminal t1/2 is defined as the time required for the plasma concentration of a drug to decrease by half of its initial concentration. Data for this outcome measure was not planned to be collected and analyzed for &quot;Ferroquine 400 mg&quot; arm, since artefenomel was not administered.</description>
          <population>Focus of PK assessment was to support the analysis of exposure versus efficacy relationship (PK and PD). Since terminal t1/2 was not considered relevant to the objective of exposure-response analysis, therefore data for this outcome measure were not collected and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Maximum Observed Plasma Concentration of Ferroquine and Its Active Metabolite SSR97213</title>
        <description>Cmax is the maximum observed plasma concentration of Ferroquine.</description>
        <time_frame>Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose</time_frame>
        <population>Analysis was performed on PK/PD efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Observed Plasma Concentration of Ferroquine and Its Active Metabolite SSR97213</title>
          <description>Cmax is the maximum observed plasma concentration of Ferroquine.</description>
          <population>Analysis was performed on PK/PD efficacy population.</population>
          <units>nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.99" spread="61"/>
                    <measurement group_id="O2" value="79.95" spread="93"/>
                    <measurement group_id="O3" value="72.64" spread="88"/>
                    <measurement group_id="O4" value="82.45" spread="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SSR97213</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.58" spread="61"/>
                    <measurement group_id="O2" value="22.65" spread="83"/>
                    <measurement group_id="O3" value="19.14" spread="99"/>
                    <measurement group_id="O4" value="19.76" spread="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Time to Reach Maximum Plasma Concentration of Ferroquine and Its Active Metabolite SSR97213</title>
        <description>tmax is the time taken by the drug to reach the maximum plasma concentration.</description>
        <time_frame>Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose</time_frame>
        <population>Focus of PK assessment was to support the analysis of exposure versus efficacy relationship (PK and PD). Since tmax was not considered relevant to the objective of exposure-response analysis, therefore data for this outcome measure were not collected and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Time to Reach Maximum Plasma Concentration of Ferroquine and Its Active Metabolite SSR97213</title>
          <description>tmax is the time taken by the drug to reach the maximum plasma concentration.</description>
          <population>Focus of PK assessment was to support the analysis of exposure versus efficacy relationship (PK and PD). Since tmax was not considered relevant to the objective of exposure-response analysis, therefore data for this outcome measure were not collected and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Plasma Concentration at 168 Hours Post-dose of Ferroquine and Its Active Metabolite SSR97213</title>
        <description>The observed plasma concentration of FQ and SSR97213 post 168 hours of FQ administration.</description>
        <time_frame>At 168 hours post-dose</time_frame>
        <population>Analysis was performed on PK/PD efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Plasma Concentration at 168 Hours Post-dose of Ferroquine and Its Active Metabolite SSR97213</title>
          <description>The observed plasma concentration of FQ and SSR97213 post 168 hours of FQ administration.</description>
          <population>Analysis was performed on PK/PD efficacy population.</population>
          <units>nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.86" spread="44"/>
                    <measurement group_id="O2" value="18.32" spread="42"/>
                    <measurement group_id="O3" value="18.69" spread="52"/>
                    <measurement group_id="O4" value="17.83" spread="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SSR97213</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.15" spread="51"/>
                    <measurement group_id="O2" value="16.03" spread="68"/>
                    <measurement group_id="O3" value="15.2" spread="78"/>
                    <measurement group_id="O4" value="14.95" spread="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration Curve Form Time 0 to Day 28 (AUC0-28) of Ferroquine and Its Active Metabolite SSR97213</title>
        <description>Area under the plasma concentration versus time curve from time 0 to Day 28 (i.e. 672 hours).</description>
        <time_frame>Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose</time_frame>
        <population>Analysis was performed on PK/PD efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Curve Form Time 0 to Day 28 (AUC0-28) of Ferroquine and Its Active Metabolite SSR97213</title>
          <description>Area under the plasma concentration versus time curve from time 0 to Day 28 (i.e. 672 hours).</description>
          <population>Analysis was performed on PK/PD efficacy population.</population>
          <units>micrograms*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.874" spread="42"/>
                    <measurement group_id="O2" value="10.33" spread="40"/>
                    <measurement group_id="O3" value="10.13" spread="51"/>
                    <measurement group_id="O4" value="10.14" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SSR97213</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.878" spread="48"/>
                    <measurement group_id="O2" value="9.051" spread="56"/>
                    <measurement group_id="O3" value="8.483" spread="68"/>
                    <measurement group_id="O4" value="8.487" spread="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration Curve From Time 0 to Infinity of Ferroquine and Its Active Metabolite SSR97213</title>
        <description>Area under the plasma concentration versus time curve from time 0 to infinity.</description>
        <time_frame>Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose</time_frame>
        <population>Analysis was performed on PK/PD efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Curve From Time 0 to Infinity of Ferroquine and Its Active Metabolite SSR97213</title>
          <description>Area under the plasma concentration versus time curve from time 0 to infinity.</description>
          <population>Analysis was performed on PK/PD efficacy population.</population>
          <units>micrograms*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="47"/>
                    <measurement group_id="O2" value="17.81" spread="43"/>
                    <measurement group_id="O3" value="16.3" spread="63"/>
                    <measurement group_id="O4" value="16.87" spread="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SSR97213</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.58" spread="53"/>
                    <measurement group_id="O2" value="20.09" spread="48"/>
                    <measurement group_id="O3" value="17.94" spread="69"/>
                    <measurement group_id="O4" value="18.32" spread="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Terminal Half-life of Ferroquine</title>
        <description>Terminal t1/2 is defined as the time required for the plasma concentration of a drug to decrease by half of its initial concentration.</description>
        <time_frame>Pre-dose, 1, 4, 6, 8, 12, 24, 72, 168, 336 and 672 hours post-dose</time_frame>
        <population>Focus of PK assessment was to support the analysis of exposure versus efficacy relationship (PK and PD). Since terminal t1/2 was not considered relevant to the objective of exposure-response analysis, therefore data for this outcome measure were not collected and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferroquine 400 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
          </group>
          <group group_id="O3">
            <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
          </group>
          <group group_id="O4">
            <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
            <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Terminal Half-life of Ferroquine</title>
          <description>Terminal t1/2 is defined as the time required for the plasma concentration of a drug to decrease by half of its initial concentration.</description>
          <population>Focus of PK assessment was to support the analysis of exposure versus efficacy relationship (PK and PD). Since terminal t1/2 was not considered relevant to the objective of exposure-response analysis, therefore data for this outcome measure were not collected and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline up to Day 28</time_frame>
      <desc>Reported AEs were TEAEs, defined as AEs that developed/worsened or became serious during on-treatment phase - defined as the time from the start of the first dose of study drug administration up to Day 28. Analysis was performed on safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ferroquine 400 mg</title>
          <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.</description>
        </group>
        <group group_id="E2">
          <title>Ferroquine 400 mg + Artefenomel 300 mg</title>
          <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.</description>
        </group>
        <group group_id="E3">
          <title>Ferroquine 400 mg + Artefenomel 600 mg</title>
          <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.</description>
        </group>
        <group group_id="E4">
          <title>Ferroquine 400 mg + Artefenomel 1000 mg</title>
          <description>On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <phone>800-633-1610 ext 1#</phone>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

